4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

Abstract

Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3 years and a 5-year survival of only 25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4-6]. The better survival is seen in an environment with access to the best available care and particularly in de novo ABC, while recurrent ABC seems to become harder to manage [7, 8].

Keywords

Affiliated Institutions

• International Breast Cancer Study Group CH
• University of Milan IT
• UCSF Helen Diller Family Comprehensive Cancer Center US
• Universidad Latinoamericana MX
• American University of Beirut Medical Center LB
• Champalimaud Foundation PT
• Consorci Institut D'Investigacions Biomediques August Pi I Sunyer ES
• Brighton and Sussex Medical School GB
• Aarhus University Hospital DK
• Vall d'Hebron Hospital Universitari ES
• Advanced Pharma US
• Dana-Farber Brigham Cancer Center US
• Clinique de Genolier CH
• Pontifícia Universidade Católica do Rio Grande do Sul BR
• Ospedale di Prato Santo Stefano IT
• Uganda Cancer Institute UG
• Centre Eugène Marquis FR
• Royal Marsden NHS Foundation Trust GB
• Ludwig-Maximilians-Universität München DE
• Karolinska Institutet SE
• European School of Oncology IT
• Peter MacCallum Cancer Centre AU
• Stanford Medicine US
• Sheba Medical Center IL
• Breast Cancer Network Australia AU
• Martin Luther University Halle-Wittenberg DE
• The Medical Oncology Centre of Rosebank ZA
• Karolinska University Hospital SE
• Gdańsk Medical University PL
• European Institute of Oncology IT
• Stanford University US
• Institut Gustave Roussy FR
• University of North Carolina Health Care US
• BC Cancer Agency CA
• Shaare Zedek Medical Center IL
• UNC Lineberger Comprehensive Cancer Center
• Dana-Farber Cancer Institute US
• The Cancer Institute Hospital JP
• Centre Jean Perrin FR
• University of Sussex GB
• Institute of Oncology Prof. Dr. Ion Chiricuta RO
• Memorial Sloan Kettering Cancer Center US
• Bombay Hospital IN
• Chinese Academy of Medical Sciences & Peking Union Medical College CN

Related Publications